Boothbay Fund Management’s Cabaletta Bio CABA Stock Holding History

Boothbay Fund Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$567K	Sell	182,455 -60,990	-25%	-$201K	0.01%	1414
2026 Q1	$655K	Hold	243,445	–	–	0.01%	1183
2025 Q4	$533K	Buy	+243,445	New	+$603K	0.01%	1102
2024 Q2	–	Sell	-10,300	Closed	-$176K	–	1548
2024 Q1	$176K	Sell	10,300 -48,455	-82%	-$1.04M	﹤0.01%	1359
2023 Q4	$1.33M	Buy	+58,755	New	+$988K	0.03%	634
2023 Q2	–	Sell	-12,528	Closed	-$104K	–	1858
2023 Q1	$104K	Sell	12,528 -1,506	-11%	-$14.1K	﹤0.01%	1922
2022 Q4	$130K	Sell	14,034 -2,988	-18%	-$10.9K	﹤0.01%	1722
2022 Q3	$11K	Sell	17,022 -73,776	-81%	-$88.8K	﹤0.01%	2180
2022 Q2	$96K	Sell	90,798 -12,552	-12%	-$17.7K	﹤0.01%	1994
2022 Q1	$210K	Hold	103,350	–	–	﹤0.01%	1851
2021 Q4	$392K	Sell	103,350 -16,584	-14%	-$177K	0.01%	1125
2021 Q3	$1.46M	Buy	119,934 +6,285	+6%	+$58K	0.04%	578
2021 Q2	$977K	Buy	113,649 +68,794	+153%	+$676K	0.03%	705
2021 Q1	$498K	Buy	+44,855	New	+$548K	0.02%	951

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Boothbay Fund Management's CABA Position: Q2 2026 in Review

Boothbay Fund Management reduced its Cabaletta Bio (CABA) stake by 25% in Q2 2026, selling an estimated $201K and leaving 182,455 shares worth $567K. The position accounts for 0.01% of the portfolio, ranked #1414.

Boothbay Fund Management first reported a position in CABA in Q1 2021 and has held it in 14 quarters since. The position peaked at $1.46M in Q3 2021. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

Boothbay Fund Management held 182,455 shares of Cabaletta Bio worth $567K as of Q2 2026.
Boothbay Fund Management sold 60,990 Cabaletta Bio shares in Q2 2026, an estimated $201K.
Cabaletta Bio made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1414 holding.
Boothbay Fund Management first reported a position in Cabaletta Bio in Q1 2021 and has held it in 14 quarters since.
Boothbay Fund Management's Cabaletta Bio position peaked at $1.46M in Q3 2021.
140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.